Moreover, after we analyzed the AOR and 95% CI of clinical statuses associated with genotypic frequencies of FOXP3 rs3761548 in oral cancer patients, we found that in 856 betel quid chewers among the total 1175 oral cancer patients, carriers who with the rs3761548 polymorphic “T” variant have a lower risk to develop poorer cell differentiated grade [(AOR) (95% CI):0.592 (0.377-0.930); p = 0.023] (Table 4). This evidence concerns the gene FOXP3 and lip and oral cavity carcinoma.